Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results

Johnson & Johnson JNJ reported better-than-expected first-quarter earnings on Tuesday.

The company posted adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion, according to data from Benzinga Pro.

Johnson & Johnson also raised its quarterly dividend by 4.2% from $1.19 per share to $1.24 per share.

Johnson & Johnson said it expects fiscal year 2024 operational sales of $88.7 billion-$89.1 billion versus prior guidance of $88.2 billion–$89.0 billion and consensus of $88.43 billion. The company expects fiscal year 2024 adjusted EPS of $10.57–$10.72 versus consensus of $10.66 and prior guidance of $10.55–$10.75, with adjusted operational EPS of $10.60–$10.75.

Johnson & Johnson shares fell 0.2% to trade at $144.12 on Wednesday.

These analysts made changes to their price targets on Johnson & Johnson following earnings announcement.

  • B of A Securities cut the price target on Johnson & Johnson from $180 to $170. B of A Securities analyst Geoff Meacham maintained a Neutral rating.
  • RBC Capital slashed the price target on Johnson & Johnson from $181 to $175. RBC Capital analyst Shagun Singh maintained an Outperform rating.
  • Cantor Fitzgerald analyst Louise Chen, meanwhile, reiterated Johnson & Johnson with an Overweight and maintained a $215 price target.


Now Read This: Top 5 Tech And Telecom Stocks That May Rocket Higher This Month

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!